VBI Vaccines Inc.

VBI Vaccines — World Vaccine Congress 2024

11 slides from VBI Vaccines's conference presentation, Apr 3, 2024

  1. Slide 1: Early Tumor Response Data from the Randomized, Controlled Phase 2b Trial of VBI-1901

    Slide 1: Early Tumor Response Data from the Randomized, Controlled Phase 2b Trial of VBI-1901

    UG ~ Vv B | Zmy VACCINES Zin ACTIVATING THE POWER WITHIN Early Tumor Response Data from the Randomized, Controlled Phase 2b Trial of VBI- 1901 for the Treatment of Recurrent Glioblastoma World Vaccine Congress 2024 April 3, 2024

  2. Slide 2: Forward-Looking & Safe Harbor Statements

    Slide 2: Forward-Looking & Safe Harbor Statements

    Forward-Looking & Safe Harbor Statements Certain statements in this presentation that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-look

  3. Slide 3: New Approaches are Required to Target Glioblastoma

    Slide 3: New Approaches are Required to Target Glioblastoma

    New Approaches are Required to Target Glioblastoma Glioblastoma is among the most common and aggressive malignant brain tumors Given Medical Need, Approved Therapies Needed Only to Demonstrate Some Survival Benefits Universally Fatal Brain Cancer ‘Over 30,000 new glioblastoma (GBM) diagnoses per yea

  4. Slide 4: Antigen Selection is Critical to Restimulate Immunity

    Slide 4: Antigen Selection is Critical to Restimulate Immunity

    Antigen Selection is Critical to Restimulate Immunity and Redirect to the Tumor Microenvironment Cancer vaccines have been proven to enhance Checkpoint Inhibitor efficacy when appropriate antigen(s) are targeted Checkpoint Inhibitors + vaccination with poorly immunogenic antigens (gp100) did Checkpo

  5. Slide 5: Cytomegalovirus (CMV) is a Highly Immunogenic Viral Target Present in Over 90% of GBM Tumors

    Slide 5: Cytomegalovirus (CMV) is a Highly Immunogenic Viral Target Present in Over 90% of GBM Tumors

    Cytomegalovirus (CMV) is a Highly Immunogenic Viral Target Present in Over 90% of GBM Tumors Using a variety of techniques, multiple labs have confirmed the presence of CMV antigens in GBM tumor samples, but not in adjacent healthy tissue! Immuno-histochemical staining of CMV pp65 antigen in a GBM s

  6. Slide 6: Our Approach to Cancer Vaccines is Differentiated from Historical Attempts to Treat GBM

    Slide 6: Our Approach to Cancer Vaccines is Differentiated from Historical Attempts to Treat GBM

    Our Approach to Cancer Vaccines is Differentiated from Historical Attempts to Treat GBM Shortcomings of Past Cancer | Vaccine Approaches n Previous cancer vaccines have failed in GBM studies due to poorly immunogenic delivery, which lacked: + Inherent potency + Balanced immunity + Breadth VBI's Enve

  7. Slide 7: Design & Objectives: Ongoing Phase 1/2 Study in Recurrent GBM Patients

    Slide 7: Design & Objectives: Ongoing Phase 1/2 Study in Recurrent GBM Patients

    Design & Objectives : Ongoing Phase 1/2 Study in Recurrent GBM Patients Phase 2a (Part B) : Phase 2b (Part C) : Extension Phase Randomized, Controlled Phase Phase 1 (Part A) Dose-Escalation Phase Study Arm 1: High Dose (n=30) 10.0g + GM-CSF vs. Study Arm 1: Low Dose (n=6) Study Arm 1: High Dose (n=1

  8. Slide 8: Data from Part A & B of Ongoing Phase 1/2 Study

    Slide 8: Data from Part A & B of Ongoing Phase 1/2 Study

    Data from Part A & B of Ongoing Phase 1/2 Study As at August 1, 2023 Based on the below results, U.S. FDA granted Fast Track Designation and Orphan Drug Designation to VBI- 1901 + GM-CSF for the treatment of recurrent GBM patients with first tumor recurrence jor Responses High Dose: Parts A & 8 Dise

  9. Slide 9: Early Tumor Response Data from Part C (Phase 2b) of Ongoing Phase 1/2 Study

    Slide 9: Early Tumor Response Data from Part C (Phase 2b) of Ongoing Phase 1/2 Study

    Early Tumor Response Data from Part C (Phase 2b) of Ongoing Phase 1/2 Study 17 patients have been randomized and received first dose of treatment as of March 22, 2024 N=8 : Standard-of-Care (SoC) arm (Carmustine or lomustine) N=9: VBI-190] arm ll patients currently evaluable for tumor response asses

  10. Slide 10: Summary and Next Steps for VBI-1901

    Slide 10: Summary and Next Steps for VBI-1901

    Summary and Next Steps for VBI-1901 Summary of Part A&B Early Data from Part C Next Steps ~5-month improvement in mOS observed vs. historical standard-of- care (12.9 months vs. 8 months) 12-month O$ : 62.5% (n=10/16) 2 partial tumor responses (PRs) 93% tumor reduction seen in one patient who remaine

  11. Slide 11: VBI Vaccines Inc.

    Slide 11: VBI Vaccines Inc.

    WP =VBI Amy YY Wy 7M A! VBI Vaccines Inc. | www.vbivaccines.com

Source: SEC EDGAR · 8-K filed Apr 3, 2024

More decks from VBI Vaccines Inc.